Empire Genomics, a Buffalo-based life sciences company that provides clinical services and develops high-tech tests for cancer, is collaborating with Memorial Sloan Kettering Cancer Center in Manhattan and five other hospitals in a partnership meant to standardize how prostate cancer is tested and reported.
Empire Genomics is manufacturing testing kits, known as assays, for the hospitals to use in the program, which is funded by a grant from the U.S. Defense Department.
The collaboration is meant to ensure that the six hospitals all use the same testing standards. That is important for meeting the future potential of precision, or personalized, medicine, which uses genetic data and tools to tailor the treatment of prostate cancer and other cancers to individual patients, said Anthony Scarpello, Empire Genomics’ vice president of business development.
As part of this program, the hospitals periodically may send samples back to Empire’s clinical lab for proficiency testing to ensure that each hospital meets the same testing standard, Scarpello said. Empire’s role in the collaboration began this spring, he said.